Ibandronate Reduces the Surface Bone Resorption of Mandibular Bone Grafts: A Randomized Trial With Internal Controls

Jahan Abtahi; Benjamin Klintström; Eva Klintström

doi:10.1002/jbm4.10468

Ibandronate Reduces the Surface Bone Resorption of Mandibular Bone Grafts: A Randomized Trial With Internal Controls

JBMR Plus. 2021 Feb 10;5(3):e10468. doi: 10.1002/jbm4.10468. eCollection 2021 Mar.

Authors

Jahan Abtahi^{1

2}, Benjamin Klintström³, Eva Klintström^{2

4}

Affiliations

¹ Department of Oral & Maxillofacial Surgery and Department of Biomedical and Clinical Sciences Linköping University Linköping Sweden.
² Center for Medical Image Science and Visualization (CMIV) Linköping University Linköping Sweden.
³ Department of Biomedical Engineering and Health Systems KTH Royal Institute of Technology Stockholm Sweden.
⁴ Department of Radiology and Department of Health, Medicine and Caring Sciences Linköping University Linköping Sweden.

Abstract

Autologous bone grafts are considered the gold standard for reconstruction of the edentulous alveolar ridges. However, this procedure is associated with unpredictable bone loss caused by physiological bone resorption. Bisphosphonates are antiresorptive drugs that act specifically on osteoclasts, thereby maintaining bone density, volume, and strength. It was hypothesized that the resorption of bone grafts treated with an ibandronate solution would be less advanced than bone grafts treated with saline. Ten patients who underwent bilateral sagittal split osteotomy were included in a randomized double-blind trial with internal controls. Each patient received a bone graft treated with a solution of ibandronate on one side and a graft treated with saline (controls) contralaterally. Radiographs for the measurement of bone volume were obtained at 2 weeks and at 6 months after surgery. The primary endpoint was the difference in the change of bone volume between the control and the ibandronate bone grafts 6 months after surgery. All of the bone grafts healed without complications. One patient was excluded because of reoperation. In eight of the nine patients, the ibandronate bone grafts showed an increase in bone volume compared with baseline, with an average gain of 126 mm³ (40% more than baseline) with a range of +27 to +218 mm³. Only one ibandronate-treated graft had a decrease in bone volume (8%). In the controls, an average bone volume loss of -146 mm³ (58% of baseline) with a range of -29 to -301 mm³ was seen. In the maxillofacial field, the reconstructions of atrophic alveolar ridges, especially in the esthetical zones, are challenging. These results show that bone grafts locally treated with ibandronate solution increases the remaining bone volume. This might lead to new possibilities for the maxillofacial surgeons in the preservation of bone graft volumes and for dental implant installations. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.

Keywords: BISPHOSPHONATE; BONE GRAFT; BONE HEALING; BONE RESORPTION; OSTEOCLAST.